CareDx Company Profile (NASDAQ:CDNA)

About CareDx (NASDAQ:CDNA)

CareDx logoCareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CDNA
  • CUSIP: N/A
  • Web:
  • Market Cap: $148.39 million
  • Outstanding Shares: 22,541,000
Average Prices:
  • 50 Day Moving Avg: $4.10
  • 200 Day Moving Avg: $2.00
  • 52 Week Range: $0.76 - $6.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.27
  • P/E Growth: -0.36
Sales & Book Value:
  • Annual Revenue: $46.96 million
  • Price / Sales: 2.81
  • Book Value: $0.55 per share
  • Price / Book: 10.64
  • EBITDA: ($9,830,000.00)
  • Net Margins: -61.27%
  • Return on Equity: -85.68%
  • Return on Assets: -21.21%
  • Current Ratio: 0.37%
  • Quick Ratio: 0.25%
  • Average Volume: 757,928 shs.
  • Beta: 0.66
  • Short Ratio: 1.24

Frequently Asked Questions for CareDx (NASDAQ:CDNA)

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

How were CareDx's earnings last quarter?

CareDx, Inc. (NASDAQ:CDNA) released its earnings results on Thursday, August, 10th. The company reported ($0.19) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.19). The company earned $12.05 million during the quarter, compared to analysts' expectations of $11.87 million. CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. View CareDx's Earnings History.

Where is CareDx's stock going? Where will CareDx's stock price be in 2017?

3 brokerages have issued 1 year price targets for CareDx's stock. Their predictions range from $6.50 to $10.00. On average, they anticipate CareDx's share price to reach $7.83 in the next year. View Analyst Ratings for CareDx.

Are investors shorting CareDx?

CareDx saw a increase in short interest in September. As of September 15th, there was short interest totalling 1,102,800 shares, an increase of 55.9% from the August 31st total of 707,418 shares. Based on an average daily volume of 201,698 shares, the short-interest ratio is presently 5.5 days. Approximately 9.1% of the company's shares are short sold.

Who are some of CareDx's key competitors?

Who are CareDx's key executives?

CareDx's management team includes the folowing people:

  • Michael D. Goldberg, Independent Chairman of the Board
  • Peter Maag Ph.D., President, Chief Executive Officer, Director
  • Michael Bell, Chief Financial Officer
  • Mitchell J. Nelles Ph.D., Chief Operating Officer
  • John J. Sninsky Ph.D., Chief Scientific Officer
  • Josh DeFonzo, Chief Commercial Officer
  • Matthew J. Meyer, Chief Business Officer
  • James P. Yee M.D., Ph.D., Chief Medical Officer
  • George W. Bickerstaff III, Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director

Who owns CareDx stock?

CareDx's stock is owned by a variety of of retail and institutional investors. Top institutional investors include PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE (5.30%) and Trellus Management Company LLC (0.12%). Company insiders that own CareDx stock include Michael Brian Bell, Neil Gagnon and Peter Maag. View Institutional Ownership Trends for CareDx.

Who bought CareDx stock? Who is buying CareDx stock?

CareDx's stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought CareDx stock in the last two years include Michael Brian Bell, Neil Gagnon and Peter Maag. View Insider Buying and Selling for CareDx.

How do I buy CareDx stock?

Shares of CareDx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CareDx's stock price today?

One share of CareDx stock can currently be purchased for approximately $5.85.

MarketBeat Community Rating for CareDx (NASDAQ CDNA)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about CareDx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CareDx (NASDAQ:CDNA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.83 (33.90% upside)
Consensus Price Target History for CareDx (NASDAQ:CDNA)
Price Target History for CareDx (NASDAQ:CDNA)
Analysts' Ratings History for CareDx (NASDAQ:CDNA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Craig HallumReiterated RatingBuy$4.00 -> $10.00N/AView Rating Details
9/27/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Buy$6.50HighView Rating Details
9/26/2017Piper Jaffray CompaniesReiterated RatingOverweight$3.00 -> $7.00HighView Rating Details
6/14/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
6/14/2016MizuhoBoost Price TargetBuy$8.00 -> $12.00N/AView Rating Details
2/9/2016Janney Montgomery ScottInitiated CoverageBuy -> Buy$12.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for CareDx (NASDAQ:CDNA)
Earnings by Quarter for CareDx (NASDAQ:CDNA)
Earnings History by Quarter for CareDx (NASDAQ CDNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017Q2 2017($0.19)($0.19)$11.87 million$12.05 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.25)($0.17)$11.50 million$12.48 millionViewListenView Earnings Details
8/10/2016Q216($0.28)($0.29)$10.42 million$10.70 millionViewListenView Earnings Details
5/6/2016Q1($0.31)($0.37)$6.97 million$6.60 millionViewN/AView Earnings Details
3/24/2016Q415($0.34)($0.40)$7.44 million$6.60 millionViewListenView Earnings Details
11/11/2015Q315($0.25)($0.29)$7.34 million$7.15 millionViewListenView Earnings Details
8/10/2015Q215($0.18)($0.27)$7.28 million$7.13 millionViewListenView Earnings Details
5/12/2015Q115($0.17)($0.19)$6.82 million$7.22 millionViewListenView Earnings Details
11/10/2014Q314($0.13)$0.01$6.60 million$6.65 millionViewN/AView Earnings Details
8/27/2014Q2 14($0.13)($0.09)$6.18 million$6.78 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CareDx (NASDAQ:CDNA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.17)($0.17)($0.17)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.08)($0.08)($0.08)
(Data provided by Zacks Investment Research)


Dividend History for CareDx (NASDAQ:CDNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CareDx (NASDAQ:CDNA)
Insider Ownership Percentage: 5.40%
Institutional Ownership Percentage: 25.51%
Insider Trades by Quarter for CareDx (NASDAQ:CDNA)
Institutional Ownership by Quarter for CareDx (NASDAQ:CDNA)
Insider Trades by Quarter for CareDx (NASDAQ:CDNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Neil GagnonMajor ShareholderBuy10,642$4.00$42,568.00View SEC Filing  
9/7/2017Neil GagnonMajor ShareholderBuy6,496$3.05$19,812.80View SEC Filing  
8/28/2017Neil GagnonMajor ShareholderBuy21,448$2.77$59,410.96View SEC Filing  
8/25/2017Neil GagnonMajor ShareholderBuy35,119$2.92$102,547.48View SEC Filing  
8/15/2017Michael Brian BellCFOBuy725$1.83$1,326.75View SEC Filing  
8/15/2017Peter MaagInsiderBuy600$1.82$1,092.00View SEC Filing  
7/24/2017Neil GagnonMajor ShareholderBuy1,486$1.23$1,827.78View SEC Filing  
6/29/2017Neil GagnonMajor ShareholderBuy1,808$1.11$2,006.88View SEC Filing  
6/23/2017Neil GagnonMajor ShareholderBuy63,120$1.10$69,432.00View SEC Filing  
5/24/2017Neil GagnonMajor ShareholderBuy7,439$1.00$7,439.00View SEC Filing  
5/23/2017Neil GagnonMajor ShareholderBuy6,836$1.04$7,109.44View SEC Filing  
4/28/2017Neil GagnonMajor ShareholderBuy15,116$0.89$13,453.24View SEC Filing  
3/16/2017Neil GagnonMajor ShareholderBuy123,160$1.83$225,382.80View SEC Filing  
9/22/2016Neil GagnonMajor ShareholderBuy178,686$4.00$714,744.00View SEC Filing  
4/14/2016Neil GagnonMajor ShareholderBuy93,240$4.02$374,824.80View SEC Filing  
10/21/2015Neil Gagnonmajor shareholderBuy1,431$4.99$7,140.69View SEC Filing  
10/20/2015Neil GagnonMajor ShareholderBuy1,347$4.92$6,627.24View SEC Filing  
9/29/2015Neil Gagnonmajor shareholderBuy6,332$6.10$38,625.20View SEC Filing  
9/4/2015Neil GagnonMajor ShareholderBuy69,383$6.95$482,211.85View SEC Filing  
6/5/2015Neil GagnonMajor ShareholderBuy6,500$5.69$36,985.00View SEC Filing  
6/1/2015Peter MaagCEOBuy2,000$4.84$9,680.00View SEC Filing  
4/17/2015Neil GagnonMajor ShareholderBuy13,051$5.34$69,692.34View SEC Filing  
3/20/2015Neil GagnonMajor ShareholderBuy6,324$6.35$40,157.40View SEC Filing  
2/27/2015Neil GagnonMajor ShareholderBuy4,270$6.03$25,748.10View SEC Filing  
2/6/2015Neil GagnonMajor ShareholderBuy4,586$7.20$33,019.20View SEC Filing  
2/5/2015Neil GagnonMajor ShareholderBuy121,587$7.10$863,267.70View SEC Filing  
2/4/2015Neil GagnonMajor ShareholderBuy31,991$7.00$223,937.00View SEC Filing  
2/3/2015Neil GagnonMajor ShareholderBuy23,558$7.03$165,612.74View SEC Filing  
2/2/2015Neil GagnonMajor ShareholderBuy3,620$7.05$25,521.00View SEC Filing  
1/29/2015Neil GagnonMajor ShareholderBuy15,395$7.04$108,380.80View SEC Filing  
1/27/2015Neil GagnonMajor ShareholderBuy84,720$7.00$593,040.00View SEC Filing  
1/22/2015Neil GagnonMajor ShareholderBuy48,670$7.13$347,017.10View SEC Filing  
1/20/2015Neil GagnonMajor ShareholderBuy16,192$6.66$107,838.72View SEC Filing  
1/15/2015Neil GagnonMajor ShareholderBuy39,109$6.43$251,470.87View SEC Filing  
1/14/2015Neil GagnonMajor ShareholderBuy122,319$7.07$864,795.33View SEC Filing  
7/22/2014Ken LudlumCFOBuy7,000$10.00$70,000.00View SEC Filing  
7/22/2014Michael GoldbergDirectorBuy25,000$10.00$250,000.00View SEC Filing  
7/22/2014Perkins Caufield & Bye KleinerMajor ShareholderBuy52,770$10.00$527,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CareDx (NASDAQ:CDNA)
Latest Headlines for CareDx (NASDAQ:CDNA)
DateHeadline logoResearch Analysts Offer Predictions for CareDx, Inc.'s Q1 2018 Earnings (CDNA) - October 13 at 11:10 AM logoETFs with exposure to CareDx, Inc. : October 10, 2017 - October 11 at 6:35 PM logoCraig Hallum Reaffirms "Buy" Rating for CareDx, Inc. (CDNA) - October 9 at 10:02 AM logoNeil Gagnon Buys 10,642 Shares of CareDx, Inc. (CDNA) Stock - October 6 at 8:16 PM logoHow Does CareDx Inc (CDNA) Affect Your Portfolio Returns? - October 5 at 9:05 PM logoCareDx's Lower Priced Stock Offering Attracts Buyers At Higher Prices - October 5 at 4:04 PM logo$11.99 Million in Sales Expected for CareDx, Inc. (CDNA) This Quarter - October 5 at 1:24 AM logoShort Interest in CareDx, Inc. (CDNA) Increases By 55.9% - September 29 at 1:56 AM logoUPDATE: CareDx, Inc (CDNA) PT Raised to $7 at Piper Jaffray - - September 27 at 10:35 PM logoPAREXEL's Acquisition by Pamplona Approved by Shareholders - September 27 at 5:34 PM logoCareDx, Inc. (CDNA) Lifted to "Outperform" at Raymond James Financial, Inc. - September 27 at 12:22 PM logoCareDx Inc (CDNA) Given "Overweight" Rating at Piper Jaffray Companies - September 26 at 5:38 PM logoMedicare reimbursement cuts slam stocks of lab services companies - September 26 at 4:06 PM logoMolDX sets AlloSure reimbursement at 2017 AlloMap level - September 26 at 8:59 AM logoETFs with exposure to CareDx, Inc. : September 25, 2017 - September 25 at 7:40 PM logoAlloMap’s Medicare reimbursement to increase in 2018 - September 22 at 9:06 PM logoHave Investors Already Priced In CareDx Inc’s (CDNA) Growth? - September 22 at 10:16 AM logoThis Market Knows No Fear - September 21 at 4:52 PM logoETFs with exposure to CareDx, Inc. : September 14, 2017 - September 14 at 10:51 PM logoCareDx, Inc. :CDNA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 - September 13 at 6:14 PM logoCareDx, Inc. (CDNA) Major Shareholder Neil Gagnon Buys 6,496 Shares - September 8 at 4:22 PM logoComparing CareDx (CDNA) and InVitae Corp (NVTA) - September 5 at 2:22 AM logoHead-To-Head Review: CareDx (CDNA) & Lion Biotechnologies (IOVA) - September 1 at 12:28 AM logoInsider Buying: CareDx, Inc. (CDNA) Major Shareholder Buys 21,448 Shares of Stock - August 30 at 4:20 PM logoCareDx, Inc. (CDNA) Major Shareholder Neil Gagnon Buys 35,119 Shares - August 28 at 7:42 PM logoCareDx Confirms AlloSure Will Receive Medicare Coverage Effective October 9th, 2017 - August 24 at 5:09 PM logoCareDx (CDNA) versus Vermillion (VRML) Financial Survey - August 21 at 10:22 PM logoEdited Transcript of CDNA earnings conference call or presentation 10-Aug-17 8:30pm GMT - August 11 at 5:31 PM logo Analysts Expect CareDx, Inc. (CDNA) Will Announce Quarterly Sales of $12.01 Million - August 11 at 4:04 PM logoCareDx, Inc. (NASDAQ:CDNA) Releases Earnings Results, Meets Expectations - August 11 at 2:34 PM logoInvestor Network: CareDx, Inc. to Host Earnings Call - August 10 at 11:13 PM logoCareDx Reports Second Quarter 2017 Financial Results - August 10 at 11:13 PM logoComparing Digiliti Money (DGLT) & CareDx (NASDAQ:CDNA) - August 10 at 8:22 PM logoCritical Analysis: Lion Biotechnologies (IOVA) versus CareDx (NASDAQ:CDNA) - August 10 at 3:20 PM logo-$0.20 EPS Expected for CareDx, Inc. (CDNA) This Quarter - August 9 at 7:46 AM logoCareDx Describes Extensive Analytical Validation Data on AlloSure Robustness at American Association of Clinical Chemistry Annual Meeting - August 4 at 5:17 PM logoCareDx, Inc. (NASDAQ:CDNA) Scheduled to Post Earnings on Tuesday - August 1 at 7:16 AM logoAnalyzing Vermillion (VRML) & CareDx (CDNA) - July 28 at 7:53 AM logoCareDx to Announce Second Quarter 2017 Financial Results on August 10, 2017 - July 27 at 4:28 PM logo$11.87 Million in Sales Expected for CareDx, Inc. (NASDAQ:CDNA) This Quarter - July 22 at 12:44 PM logoReviewing CareDx (CDNA) and Digiliti Money (DGLT) - July 21 at 12:06 AM logo-$0.20 Earnings Per Share Expected for CareDx, Inc. (NASDAQ:CDNA) This Quarter - July 20 at 9:15 AM logo100,000th AlloMap Result Provided to Heart Transplant Patients - July 13 at 6:03 PM logoAsset Acquisitions Accelerate in Healthcare Sector Boosting Potential Revenue Growth - July 11 at 6:05 PM logoETFs with exposure to CareDx, Inc. : July 10, 2017 - July 10 at 5:01 PM logoCareDx Restructures and Defers Certain Obligations to March 2019 - July 3 at 5:03 PM logoCareDx (CDNA) Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule - May 24 at 9:07 PM logoCareDx (CDNA) Names Michael Bell as New CFO - April 22 at 4:06 PM logoMid-Afternoon Market Update: Oracle Gains On Earnings Beat; TrovaGene Shares Slide - March 16 at 5:33 PM logoCAREDX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agr - March 15 at 4:32 PM



CareDx (CDNA) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.